Distinct Clinical Phenotypes and Treatment Responses in IgG4 ‐Related Disease: Insights From a Tertiary Care Centre in Western India
International Journal of Rheumatic Diseases · 2026-05 · 29 (5)
DOI: 10.1111/1756-185x.70710 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 25.05.2026. Verfasst von Sandeep Yadav und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease, Glucocorticoids, Immunosuppressive Agents. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
IgG4‐related disease (IgG4‐RD) is a rare fibroinflammatory disorder characterized by tumefactive lesions and IgG4+ plasma cell infiltration. While corticosteroids induce remission, high relapse rates necessitate steroid‐sparing agents. Although well‐studied in East Asia, comprehensive Indian data remain limited.
Methods
This retrospective study (2018–2024) analyzed 60 biopsy‐evaluated patients diagnosed per the 2020 Revised Comprehensive Diagnostic Criteria. All received glucocorticoid induction; steroid‐sparing agents were initiated concurrently in 97%. Treatment response was assessed using the IgG4‐RD Responder Index (complete response [CR]: RI < 3 with ≥ 2‐point reduction; partial response [PR]: ≥ 2‐point reduction with RI ≥ 3; relapse: ≥ 2‐point rise after response).
Results
The cohort ( n = 60) was 57% male, mean age of 46.4 ± 16.1 years. Most had definite IgG4‐RD (63%), and 42% presented with multisystem involvement. Distinct from East Asian cohorts, retroperitoneal fibrosis (32%) and lung involvement (28%) predominated, with pancreatic (5% vs. 60% in Japan) and salivary gland disease (25% vs. 72%) were rare. Histopathology revealed universal lymphoplasmacytic infiltrates (100%) and fibrosis (93%), but infrequent storiform fibrosis (7%) and obliterative phlebitis (12%). Treatment yielded a 90% response rate at 6 months (28% CR, 62% PR), improving to 52% CR at 2 years. Despite excellent induction, cumulative relapse reached 66% at a median of 13 months follow‐up, underscoring the disease's chronic nature. In a small subgroup receiving rituximab plus methotrexate ( n = 4), 75% achieved CR with no documented relapses at 2 years; larger studies are needed to confirm this signal. One death occurred from urosepsis.
Conclusion
Indian IgG4‐RD patients exhibit younger onset, retroperitoneal‐lung predominance, and minimal pancreatic involvement. Early combination immunosuppression provides excellent initial responses but cannot prevent the disease's relapsing nature, underscoring the need for long‐term maintenance strategies and region‐specific management approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India.
ORCID-Profile: Sandeep Yadav, Girija Sachdev, C Balakrishnan, Rohini Samant, Gurmeet Mangat
Zitieren
APA
Yadav, S., Sachdev, G., Balakrishnan, C., Samant, R., & Mangat, G. (2026). Distinct Clinical Phenotypes and Treatment Responses in IgG4 ‐Related Disease: Insights From a Tertiary Care Centre in Western India. International Journal of Rheumatic Diseases, 29(5). https://doi.org/10.1111/1756-185x.70710
Vancouver
Yadav S, Sachdev G, Balakrishnan C, Samant R, Mangat G. Distinct Clinical Phenotypes and Treatment Responses in IgG4 ‐Related Disease: Insights From a Tertiary Care Centre in Western India. International Journal of Rheumatic Diseases. 2026;29(5). doi:10.1111/1756-185x.70710
BibTeX
@article{Yadav2026,
author = {Yadav, Sandeep and Sachdev, Girija and Balakrishnan, C and Samant, Rohini and Mangat, Gurmeet},
title = {Distinct Clinical Phenotypes and Treatment Responses in IgG4 ‐Related Disease: Insights From a Tertiary Care Centre in Western India},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
volume = {29},
number = {5},
doi = {10.1111/1756-185x.70710}
}
EUVIMED